BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35128203)

  • 1. Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab.
    Thompson EW; Demissei BG; Smith AM; Brahmbhatt P; Wang J; Clark A; DeMichele A; Narayan V; Shah P; Sun L; Lefebvre B; Fradley MG; Carver JR; Tang WHW; Ky B
    JACC Basic Transl Sci; 2022 Jan; 7(1):1-10. PubMed ID: 35128203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
    Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
    JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
    Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.
    Finkelman BS; Putt M; Wang T; Wang L; Narayan H; Domchek S; DeMichele A; Fox K; Matro J; Shah P; Clark A; Bradbury A; Narayan V; Carver JR; Tang WHW; Ky B
    J Am Coll Cardiol; 2017 Jul; 70(2):152-162. PubMed ID: 28683962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction.
    Demissei BG; Fan Y; Qian Y; Cheng HG; Smith AM; Shimamoto K; Vedage N; Narayan HK; Scherrer-Crosbie M; Davatzikos C; Ky B
    Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):418-426. PubMed ID: 33206976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
    Beer LA; Kossenkov AV; Liu Q; Luning Prak E; Domchek S; Speicher DW; Ky B
    Circ Res; 2016 Oct; 119(10):1135-1144. PubMed ID: 27582370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
    J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.
    Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN
    Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
    Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
    JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin.
    Lee SH; Cho I; You SC; Cha MJ; Chang JS; Kim WD; Go KY; Kim DY; Seo J; Shim CY; Hong GR; Kang SM; Ha JW; Rha SY; Kim HS
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.
    Nakayama T; Oshima Y; Shintani Y; Yamamoto J; Yokoi M; Ito T; Wakami K; Kitada S; Goto T; Hashimoto H; Kusumoto S; Sugiura T; Iida S; Seo Y
    Circ Rep; 2022 Apr; 4(4):173-182. PubMed ID: 35434414
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
    Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
    Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction.
    Esteban-Fernández A; Carvajal Estupiñan JF; Gavira-Gómez JJ; Pernas S; Moliner P; Garay A; Sánchez-González Á; Fernández-Rozas I; González-Costello J
    Front Cardiovasc Med; 2021; 8():721080. PubMed ID: 34778393
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies.
    Kunutsor SK; Bakker SJ; James RW; Dullaart RP
    Atherosclerosis; 2016 Feb; 245():143-54. PubMed ID: 26724525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
    Suntheralingam S; Fan CS; Calvillo-Argüelles O; Abdel-Qadir H; Amir E; Thavendiranathan P
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy.
    Laufer-Perl M; Arnold JH; Mor L; Amrami N; Derakhshesh M; Moshkovits Y; Sadeh B; Arbel Y; Topilsky Y; Rozenbaum Z
    Clin Res Cardiol; 2020 Feb; 109(2):255-262. PubMed ID: 31214777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction.
    Milks MW; Velez MR; Mehta N; Ishola A; Van Houten T; Yildiz VO; Reinbolt R; Lustberg M; Smith SA; Orsinelli DA
    Am J Cardiol; 2018 Apr; 121(7):867-873. PubMed ID: 29454478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.